The grant application called "aiREAD – Accurate and Intelligent Reading for EArlier breast cancer Detection” by project leader Ioannis Sechopoulos, has been selected for funding under the NWO TTW – KWF Kankerbestrijding – Top Sector LSH Partnership “Technology for Oncology II”.
By developing and applying new artificial intelligence methods, and advancing our knowledge on human visual perception of medical images, the investigators will improve how radiologists read breast cancer screening mammograms. Optimal reading of the screening mammograms will result in earlier detection of breast cancer, fewer healthy women recalled due to false alarms, and savings in the costs of healthcare.
Lead by Ioannis Sechopoulos, the project team consists of Jonas Teuwen, from the Department of Radiology and Nuclear Medicine, Mireille Broeders (Department for Health Evidence and the Dutch Expert Centre for Screening, LRCB), Ruud Pijnappel (UMC Utrecht and LRCB), Lucien Duijm (Canisius Wilhelmina Hospital and LRCB), and Craig Abbey and Miguel Eckstein (both from University of California, Santa Barbara, USA).
Read more on the NWO website (in Dutch).
Ioannis Sechopoulos is a member of theme Women's cancers and the LRCB, and leader of the AXTI laboratory.
Related news items
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.read more
Michiel Vermeulen and Klaas Mulder receive funding from ZonMw for a collaborative project using stem cell-based models15 July 2021
Michiel Vermeulen and Klaas Mulder, theme Cancer development and immune defense, receive funding from ZonMw for a collaborative project to develop a stem cell based model to study early human embryogenesis.read more
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development15 July 2021
The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortiumread more